Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1‐rearranged lung cancer

Tyrosine kinase inhibitors (TKIs) that target the ROS proto‐oncogene 1, receptor tyrosine kinase (ROS1) gene have shown dramatic therapeutic effects in patients with ROS1‐rearranged non‐small‐cell lung cancer (NSCLC). Nevertheless, advanced ROS1‐rearranged NSCLC is rarely cured as a portion of the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazoe, Masatoshi, Ozasa, Hiroaki, Tsuji, Takahiro, Funazo, Tomoko, Yoshida, Hiroshi, Hashimoto, Kentaro, Hosoya, Kazutaka, Ogimoto, Tatsuya, Ajimizu, Hitomi, Yoshida, Hironori, Itotani, Ryo, Sakamori, Yuichi, Kuninaga, Kiyomitsu, Aoki, Wataru, Hirai, Toyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899615/
https://www.ncbi.nlm.nih.gov/pubmed/36285485
http://dx.doi.org/10.1111/cas.15622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899615/
https://www.ncbi.nlm.nih.gov/pubmed/36285485
http://dx.doi.org/10.1111/cas.15622

Ejemplares similares